Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables.
Fluoxetine (60 mg), a selective inhibitor of the reuptake of 5-HT, was compared in a double-blind trial to amitriptyline (150 mg) in a sample of 34 patients fitting the Research Diagnostic Criteria for a major depressive disorder. Patients were studied after a drug washout period of 10 days and an active treatment period of 42 days. Sleep polygraphic recordings were performed before and at the end of the study. As indicated by the significant decrease in the Hamilton Depression scale and the Montgomery Asberg Depression scale, fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects. Fluoxetine and amitriptyline decreased the amount of REM sleep, a well known effect of classical antidepressants. Fluoxetine showed some specific effects on sleep continuity (potentially dose related) as indicated by the significant increase in the number of awakenings and in stage shifts, without interfering with the therapeutic response.
Kerkhofs
M
M
Sleep Laboratory Department of Psychiatry, Erasme Hospital, Bruxelles, Belgium.
Rielaert
C
C
de Maertelaer
V
V
Linkowski
P
P
Czarka
M
M
Mendlewicz
J
J
D000293:Adolescent; D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012890:Sleep / Q000187:drug effects*
D005473:Fluoxetine; D000639:Amitriptyline